Valuation: Aradigm Corporation

Market Cap 48.85L 42.69L 39.4L 36.31L 68.44L 47Cr 69.96L 4.71Cr 1.85Cr 23Cr 1.83Cr 1.79Cr 79Cr P/E 2016
-0.72x
P/E 2017 -9.3x
Enterprise Value 1.28Cr 1.12Cr 1.03Cr 95.13L 1.79Cr 123.25Cr 1.83Cr 12Cr 4.85Cr 60Cr 4.81Cr 4.7Cr 207.8Cr EV / Sales 2016
73.3x
EV / Sales 2017 7.27x
Free-Float
60.28%
Yield 2016 *
-
Yield 2017 -
Change 5-day change 1-year change 3-year change Capi.($)
+36.88%+25.50% - - 7L
-0.53%-3.91%+0.71%+2.39% 4.92TCr
+0.20%+1.89%+387.83%+598.83% 3.96TCr
+0.82%+4.00%+8.29%+63.89% 3.47TCr
-1.09%-1.95%+28.03%-10.10% 3.44TCr
+0.06%+0.34%+2.38%+34.47% 2.71TCr
+0.25%-0.74% - - 1.62TCr
-0.04%+0.91%+73.21%+116.69% 1.54TCr
+0.31%+1.44%+14.49%+17.27% 1.41TCr
-2.03%+2.64%+22.09%-31.09% 1.3TCr
Average +3.55%+0.03%+67.13%+99.04% 2.71TCr
Weighted average by Cap. -0.15%-0.18%+80.54%+124.22%

Financials

2016 2017
Net sales 2L 2L 2L 1L 3L 1.88Cr 3L 18.8L 7L 91.97L 7L 7L 3.17Cr 1.45Cr 1.26Cr 1.17Cr 1.08Cr 2.03Cr 139.3Cr 2.07Cr 14Cr 5.48Cr 68Cr 5.43Cr 5.31Cr 234.86Cr
Net income -3.29Cr -2.88Cr -2.66Cr -2.45Cr -4.61Cr -317.2Cr -4.72Cr -32Cr -12Cr -155.35Cr -12Cr -12Cr -534.79Cr -1.07Cr -93.55L -86.33L -79.57L -1.5Cr -103.09Cr -1.53Cr -10Cr -4.06Cr -50Cr -4.02Cr -3.93Cr -173.81Cr
Net Debt -93.72L -81.9L -75.58L -69.66L -1.31Cr -90Cr -1.34Cr -9.03Cr -3.55Cr -44Cr -3.52Cr -3.44Cr -152.17Cr 79.13L 69.15L 63.81L 58.82L 1.11Cr 76Cr 1.13Cr 7.63Cr 3Cr 37Cr 2.97Cr 2.91Cr 128.48Cr
Logo Aradigm Corporation
Aradigm Corp is a United States-based company. The Company is an emerging specialty pharmaceutical company focused on the development and commercialization of drugs for the prevention and treatment of severe respiratory diseases. Its inhaled ciprofloxacin formulations are also product candidates for treatment of patients with cystic fibrosis and non-tuberculous mycobacteria, and for the prevention and treatment of high threat and bioterrorism infections, such as inhaled tularemia, pneumonic plague, melioidosis, Q fever and inhaled anthrax.
Employees
-